Suboptimal Use of Cardioprotective Medications in Patients With a History of Cancer

Modern cancer therapies have led to improved survival rates for many cancers. Rates of cardiovascular diseases (CVD) and risk factors are increased in cancer patients and survivors compared with the general population, and CVD has emerged as a leading cause of long-term morbidity and mortality in this population (1). Cardioprotective medications, including statins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and antiplatelet therapies remain cornerstones of primary and secondary CVD prevention. However, data regarding the use of cardioprotective medications among cancer patients and survivors have been inconsistent.